Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Human Genome Sciences
So what: According to British newspaper The Daily Mail, Glaxo could be poised to make a $25-per-share bid for Human Genome, representing a whopping 123% premium over its Monday closing price. Of course, The Daily Mail didn't exactly cite any sources close to the matter and both companies declined to comment, so investors shouldn't read too much into the takeover rumor.
Now what: The Daily Mail added that Merck
Interested in more info on Human Genome? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days.